Key Laboratory of Fujian-Taiwan Animal Pathogen Biology, College of Animal Sciences (College of Bee Science), Fujian Agriculture and Forestry University, Fuzhou 350002, China.
Molecules. 2021 Feb 4;26(4):810. doi: 10.3390/molecules26040810.
Influenza virus is a highly contagious zoonotic respiratory disease that causes seasonal outbreaks each year and unpredictable pandemics occasionally with high morbidity and mortality rates, posing a great threat to public health worldwide. Besides the limited effect of vaccines, the problem is exacerbated by the lack of drugs with strong antiviral activity against all flu strains. Currently, there are two classes of antiviral drugs available that are chemosynthetic and approved against influenza A virus for prophylactic and therapeutic treatment, but the appearance of drug-resistant virus strains is a serious issue that strikes at the core of influenza control. There is therefore an urgent need to develop new antiviral drugs. Many reports have shown that the development of novel bioactive plant extracts and microbial extracts has significant advantages in influenza treatment. This paper comprehensively reviews the development and effects of chemosynthetic drugs, plant extracts, and microbial extracts with influenza antiviral activity, hoping to provide some references for novel antiviral drug design and promising alternative candidates for further anti-influenza drug development.
流感病毒是一种高度传染性的人畜共患呼吸道疾病，每年都会引发季节性爆发，并偶尔引发不可预测的大流行，导致高发病率和死亡率，对全球公共卫生构成巨大威胁。除了疫苗效果有限之外，这个问题还因缺乏对所有流感株都具有强大抗病毒活性的药物而加剧。目前，有两类抗病毒药物可用于预防和治疗甲型流感病毒，但耐药病毒株的出现是一个严重的问题，这是流感控制的核心问题。因此，迫切需要开发新的抗病毒药物。许多报告表明，新型生物活性植物提取物和微生物提取物在流感治疗方面具有显著优势。本文全面综述了具有抗流感活性的化学合成药物、植物提取物和微生物提取物的开发和作用，希望为新型抗病毒药物设计提供一些参考，并为进一步开发有前途的抗流感药物提供候选药物。
